– $11.7 million award will be used to advance ALTO-100, a first-in-class small molecule, in a 200-patient placebo-controlled, double-blind, randomized Phase 2b study in bipolar depression –

– Alto will leverage the same cognitive biomarker being used in the ongoing Phase 2b MDD, which was previously identified and replicated in MDD and PTSD patients –

– This study represents the first precision psychiatry trial in bipolar depression, an indication identified by Wellcome Trust as an area of high unmet need in mental health with under-representation across drug development efforts –

Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that the Company has been awarded $11.7 million by the Wellcome Trust to advance the clinical development of lead candidate ALTO-100 through a Phase 2b study in patients with bipolar depression characterized by a cognitive biomarker. The Company has initiated this study and expects to report topline data in 2026.